Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Courts, Not FDA Panel, Likely Bigger Hurdle For Amgen's Humira Biosimilar

Executive Summary

Amgen Inc. appears to have a smooth path to FDA approval of its biosimilar of AbbVie Inc.'s tumor necrosis factor Humira (adalimumab) based on documents released ahead of a July 12 advisory committee meeting. But don't expect AbbVie to just sit back and take it.


Related Content

Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Another Strong Quarter For AbbVie, But How Long Will Good Times Last?
2Q Preview: GSK, Bayer, Celgene, Amgen, AZ, BMS, Sanofi, Merck, Abbvie
Biosimilars: Does FDA Caution Make Advisory Committee A Rubber Stamp?
Tentative-Style Approvals Coming For US Biosimilars?
AbbVie Foe Coherus Sways PTAB To Review Humira Patent
Reject AbbVie 'Interchangeable' Petition, Sandoz Tells FDA
Humira Competition Dominates AbbVie Earnings
Humira Biosimilar Under Review: Amgen, AbbVie Tango Time
Amgen Biosimilars Game On: Filing Chases AbbVie's Humira


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts